Send to

Choose Destination
See comment in PubMed Commons below
Korean J Hematol. 2010 Sep;45(3):152-7. doi: 10.5045/kjh.2010.45.3.152. Epub 2010 Sep 30.

The how's and why's of evidence based plasma therapy.

Author information

The Institute for Transfusion Medicine, Department of Pathology, University of Pittsburgh, Pittsburgh, PA, USA.


Although traditionally fresh frozen plasma (FFP) has been the product of choice for reversing a significant coagulopathy, the modern blood bank will have several different plasma preparations which should all be equally efficacious in reversing a significant coagulopathy or arresting coagulopathic bleeding. Emerging evidence suggests that for a stable patient, transfusing plasma for an INR≤1.5 does not confer a hemostatic benefit while unnecessarily exposing the patient to the risks associated with plasma transfusion. This review will discuss the various plasma products that are available and present some of the current literature on the clinical uses of plasma.


Evidence; FFP; FP24; Fresh frozen plasma; INR; PTT; Plasma; Transfusion

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Society of Hematology Icon for PubMed Central
    Loading ...
    Support Center